Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Smartphone app aims to predict and prevent COPD attacks using weather data

NCT ID NCT07656142

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a personalized mobile app that gives temperature-related health warnings and safety tips can reduce acute exacerbations (sudden worsening of symptoms) in people with chronic obstructive pulmonary disease (COPD). About 240 participants will either receive the app plus usual care or usual care alone. The main goal is to see if the app lowers the number of COPD flare-ups over one year.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
personalized mobile application with temperature-related health risk warnings
What this could lead to
If effective, this app could help people with COPD avoid acute exacerbations triggered by temperature changes, improving daily life and reducing hospital visits.
What could go wrong
This is a relatively small trial testing a behavioral intervention, not a drug. Results may vary based on user engagement, and the app may not work for everyone or in all climates.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 240 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jun 2026

An estimate. Start dates often move.

Expected to finish

Aug 2027

An estimate. End dates often move.

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

40 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Hospital inclusion criteria: 1. Tertiary hospitals; 2. Hospitals with respiratory wards that admit patients with COPD; 3. Hospitals with a well-established electronic health record system and follow-up capability; 4. Hospitals able to assign a study coordinator. Patient inclusion criteria: 1. Age \>=40 years and \<=80 years, with no restriction on sex; 2. Patients with stable chronic obstructive pulmonary disease; 3. At least 1 severe acute exacerbation requiring hospitalization, or at least 2 moderate acute exacerbations requiring outpatient or emergency care, within the previous year; 4. Local permanent residents with a duration of residence \>=6 months; 5. Patients who voluntarily agree to participate, are expected to have good adherence, are able to sign informed consent; 6. Patients who own a smartphone or other smart device. Hospital exclusion criteria: 1. Primary hospitals or private hospitals; 2. Hospitals unable to cooperate with the study protocol. Patient exclusion criteria: 1. Patients with asthma; 2. Women who are known to be pregnant or breastfeeding, or who have a positive pregnancy test before cluster randomization; 3. Patients with other diseases that may affect participation in the trial, such as refractory hypertension or severe aphasia; 4. Patients currently receiving psychiatric or psychological treatment that may contaminate study results; 5. Expected survival time \<1 year, such as in those with malignant tumors or severe cardiopulmonary disease; 6. Participation in other interventional clinical studies that may affect outcome assessment; 7. Any other circumstances in which the investigator considers the patient unsuitable for participation in this study or at significant risk, such as cognitive impairment preventing understanding of and/or compliance with study procedures and/or follow-up.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic obstructive pulmonary disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.